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In a rare life-threatening disease setting the number of patients in the trial is a high propor-
tion of all patients with the condition (if not all of them). Further, this number is usually
not enough to guarantee the required statistical power to detect a treatment eﬀect of a
meaningful size. In such a context, the idea of prioritizing patient beneﬁt over hypothesis
testing as the goal of the trial can lead to a trial design that produces useful information to
guide treatment, even if it does not do so with the standard levels of statistical conﬁdence.
The idealized model to consider such an optimal design of a clinical trial is known as a
classic multi-armed bandit problem with a ﬁnite patient horizon and a patient beneﬁt
objective function. Such a design maximizes patient beneﬁt by balancing the learning and
earning goals as data accumulates and given the patient horizon. On the other hand, opti-
mally solving such a model has a very high computational cost (many times prohibitive)
and more importantly, a cumbersome implementation, even for populations as small as a
hundred patients. Several computationally feasible heuristic rules to address this problem
have been proposed over the last 40 years in the literature. In this paper, we study a novel
heuristic approach to solve it based on the reformulation of the problem as a Restless ban-
dit problem and the derivation of its corresponding Whittle Index (WI) rule. Such rule was
recently proposed in the context of a clinical trial in Villar, Bowden, and Wason [16]. We
perform extensive computational studies to compare through both exact value calculations
and simulated values the performance of this rule, other index rules and simpler heuristics
previously proposed in the literature. Our results suggest that for the two and three-armed
case and a patient horizon less or equal than a hundred patients, all index rules are a priori
practically identical in terms of the expected proportion of success attained when all arms
start with a uniform prior. However, we ﬁnd that a posteriori, for speciﬁc values of the
parameters of interest, the index policies outperform the simpler rules in every instance
and specially so in the case of many arms and a larger, though still relatively small, total
number of patients with the diseases. The very good performance of bandit rules in terms
of patient beneﬁt (i.e., expected number of successes and mean number of patients allo-
cated to the best arm, if it exists) makes them very appealing in context of the challenge
posed by drug development and treatment for rare life-threatening diseases.
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1. INTRODUCTION
Developing speciﬁc statistical learning methods for drug development for rare diseases is
one of the most pressing modern clinical needs. Answering scientiﬁc questions for rare
conditions has long been limited mainly by the unavailability of enough patients for running
standard clinical trials. The number of patients required to run a trial is strongly inﬂuenced
by regulatory agencies, such as the FDA in the USA or the EMA in Europe, and ethical
standards as those summarized in the Belmont report. The traditional rationale behind this
minimum number comes from embracing as the main goal of the trial that of maximizing
the learning about the treatments under consideration.
The way in which such a learning goal is implemented in practice is as follows: physicians
agree on an improvement over the control response rate Δp (or treatment eﬀect) that would
be beneﬁcial to establish. Then, given that patients are randomly assigned to treatments in
a balanced fashion, the trial’s number of participants is determined as that which ensures
controlling for the probabilities rates of both a false positive (Type I error) and a true
positive (Power) associated with the chosen treatment eﬀect Δp. These rates typically are
(two-sided) 5% and at least 80%, respectively. The logic behind this widespread paradigm
is that because a number of patients much larger than those in the trial stands to beneﬁt
from the resulting learning provided by the trial, then its design should ensure conclusions
drawn by the end of it are carefully controlled.
However, for rare conditions it occurs that the size of the trial that meets these require-
ments is either larger than the current estimation of the patient population (or patient
horizon) or it would only be achieved after an excessively long recruitment period (after
which the learning from the trial would most likely be rendered irrelevant for patients with
the disease). In other words, the learning goal as a guide to trial design is usually either
impossible or absolutely impractical to achieve in rare diseases populations. There is there-
fore a real and compelling need for a new and more adequate paradigm for generating
clinical evidence and making treatment decisions for small populations, particularly when
the disease is life-threatening Wang and Arnold [18]. Such a need is starting to be acknowl-
edged by institutions worldwide, for example, the European Union has recently funded
three international, multidisciplinary research consortia aiming at the development of eﬃ-
cient statistical methods for the assessment of the safety and/or eﬃcacy of a treatment for
small population groups. More importantly, this need will become increasingly pressing as
genomic approaches continue to advance and disease categories are fragmented into ﬁner
and ﬁner entities.
If such a controlled learning goal is not feasible, then a way out of the conundrum is
to change the goal. A sensible goal of a trial involving a rare life-threatening condition is,
instead of learning in a highly controlled way, to learn enough so as to eﬀectively treat as
many patients in the population as possible. In that context, the relevant statistical question
is how much learning is necessary to best treat the whole patient population, thus moving
the focus of the trial away from that of maximum learning with a controlled conﬁdence
level. The resulting paradigm provides an alternative and feasible method to evaluate new
therapies for rare and fatal diseases and to balance the need for experimentation with the
desire to guide treatment selection toward the best treatment of a population.
Implementing such a dual learning–earning goal into a trial can be done in several ways.
In the ﬁrst place, it depends on the way the learning and earning phases are envisaged. In
Cheng, Su, and Berry [5], it is assumed that the learning and earning are two distinct
phases whose sizes are decided a priori of making any observation and that the learning
phase takes the form of a balanced randomized trial. Therefore, the optimal design question
reduces to determining the size of the experimenting stage n such that mean proportion
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of successes in the trial and the remaining population is maximized. Assuming equipoise
regarding the therapeutic eﬀectiveness of the treatments involved they show that the optimal
sample size for a randomized trial has an order of magnitude of
√
N , where N is the patient
horizon.
If, however, the size of the learning phase n is not ﬁxed in advance and the ques-
tion of balancing learning and earning is asked after every patient (i.e., the approach is
fully sequential) then the advantages, in terms of patient beneﬁt, are the highest yet treat-
ment allocation, as determined by decision analysis, is deterministic, tedious to implement
and computationally intensive. Examples of papers aiming at overcoming these limitations,
which are relevant to this paper, include Cheng and Berry [4], Villar, Wason, and Bowden
[17] and Berry [2]. In the ﬁrst two papers, authors aim at introducing randomization to
bandit-based strategies. In Cheng and Berry [4], the authors introduce randomization to
decision-analytic rules by determining optimal allocation probabilities that deviate from a
balanced randomized scheme and have a minimum value of r, with r ≤ 1/K and K being
the number of treatments in the trial. In Villar, Wason, and Bowden [17], the authors pro-
pose a fully randomized, adaptive group allocation procedure based on the optimal solution
to the classic inﬁnite horizon bandit problem. In Berry [2], the computational and imple-
mentation diﬃculties are addressed by proposing a near-optimal heuristic strategy based
on the so-called Feldman’s index (FI). For a recent review paper and a discussion of other
limitations to the application of these decision-analytic approaches known as bandit models
to clinical trial design, see Villar, Bowden, and Wason [16].
In this paper, we focus on overcoming the computational limitations of bandit-based
designs and on the performance evaluation of index-based heuristics. We extend the ideas
presented in Villar, Bowden, and Wason [16] and relate then to the work in Berry [2].
We explain how to derive near optimal heuristics for the ﬁnite-horizon Bernoulli Multi-
armed Bandit problem based on a Restless bandit reformulation of the problem and on
the Whittle and Gittins indices. We illustrate how this approach manages to reduce the
suboptimality gap (when compared with that of Feldman’s approach in Berry [2]), being
computationally feasible and relatively simple to interpret and implement. We compare it
with other heuristics and we perform various exact and simulated calculations in diﬀerent
contexts to evaluate when their application is more appropriate.
2. THE WHITTLE INDEX (WI) APPROACH
2.1. Background
Consider a patient population of size N and K experimental treatments and a control
treatment (either standard of care or placebo, represented by k = 0) under study. Patients
are assigned sequentially to treatments and the outcome of a patient j allocated to some
treatment k is observed before making the treatment decision for patient j + 1. Further, for
simplicity, suppose that the response to treatment is random and binary, that is, is either a
success (positive) or a failure (negative). Denote the probability of a success using treatment
k by pk.
The optimization problem is to ﬁnd a treatment allocation rule that speciﬁes which arm,
out of the K + 1 possible ones, will be received by each of the N patients so as to achieve
a chosen goal. Such a rule can be expressed by means of a deterministic sequence {ak,j , j =
1, . . . , N k = 0, . . . ,K}, with ak,j being a binary indicator variable denoting whether patient
j is assigned to treatment k (ak,j = 1) or not (ak,j = 0). Naturally, given that only one
treatment can be allocated per patient we impose that
∑K
k=0 ak,j = 1 for every patient j.
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Randomization of the allocation sequence could be considered by allowing for the deﬁnition
of allocation probabilities as P (ak,j = 1) but as it turns out that the optimal policy is
deterministic we shall not consider randomized policies in this paper.
Suppose that the objective of the problem is to maximize the mean proportion of
positive responses in these N patients. If every pk is known, then all the information to
make a decision is available before the start of the trial and the way to maximize the
mean proportion of successes is to allocate all patients to the treatment with the highest
success rate, in which case the maximum mean expected proportions of successes is p∗ where
p∗ = maxk:0,...,K pk. If the pk’s are unknown, as patients are treated information about the
treatments will be accumulated, which may be used to better treat patients appearing
later in time. A uniﬁed way to handle such accumulating information is to, following a
Bayesian approach, quantify the information about every pk in the form of a probability
distribution and then deﬁne an optimal treatment allocation design as that which maximizes
the proportion of successes over the N patients averaged over pk.
Let the outcome of every patient j under any treatment arm k be a K + 1-dimensional
random sequence {(X0,j ,X1,j , . . . , XK,j , j = 1, . . . , N} out of which only one element can
be observed, that is, that of the allocated treatment arm: {Zj(τ) =
∑K
k=0 a
τ
k,jXk,j , j =
1, . . . , N} where τ represents the treatment allocation rule. Applying a decision-analytic
approach and considering the utility of the design to be the proportion of successes in the
N patients, the value of a design τ is,
V (τ,N, π,K) =
E
[(∑N
j=1 Zj(τ)
)]
N
, (1)
where π is the joint prior distribution of (p0, p1, . . . , pK), which for Bernoulli-independent
arms is the product of Beta distributions Be(a, b). Naturally, the optimization problem is
therefore, to ﬁnd the design τ∗ such that
V ∗ (N,π,K) = V (τ∗, N, π,K) = max
τ∈T
E
[(∑N
j=1 Zj(τ)
)]
N
, (2)
where T is the family of admissible designs, that is, all the feasible sequences of treatment
actions {aτk,j} for all k and j.
Equation (2) deﬁnes a ﬁnite-horizon“K + 1-armed bandit” problem whose exact opti-
mal solution can only be found by applying a backwards induction algorithm to solve its
associated dynamic programming formulation. This optimal procedure is computationally
very expensive and its cost explodes as the number of experimental arms K and the popula-
tion size N grow, being unfeasible for instances as small as K = 3 and N ≥ 100. Moreover,
its implementation is highly diﬃcult since it has to specify a treatment to use in all possible
population outcome histories, that is, 2(K + 1)N situations. These are the main reasons
why approximate and simpler methods to solve these problems have long been studied and
proposed in the literature.
2.2. Index-Based Strategies: the Gittins Index (GI)
An elegant and computationally tractable solution to a variant of problem (2) that considers
an inﬁnite number of patients, that is, N =∞, and therefore, for the sake of tractability
of the value function, includes a discount factor 0 ≤ d < 1 to weigh the observed successes
across patients, was ﬁrst obtained by Gittins and Jones [9]. This was a signiﬁcant break-
through, as the result brings to the realms of computational feasibility instances of the
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Table 1. The (approximate) GI values for an information vector of
s successes and f failures, where d = 0.999 and N is truncated at
N = 1000.
f/s 1 2 3 4 5 6
1 0.9424 0.9596 0.9673 0.9719 0.9751 0.9774
2 0.8246 0.8748 0.8993 0.9145 0.9250 0.9328
3 0.7075 0.7825 0.8226 0.8483 0.8665 0.8803
4 0.6098 0.6986 0.7492 0.7834 0.8082 0.8272
5 0.5310 0.6249 0.6836 0.7236 0.7532 0.7766
6 0.4667 0.5642 0.6252 0.6696 0.7031 0.7293
multi-armed problem that were not available before via the traditional approach. The main
reason for that is that the solution to each of those K + 1 two-armed problems is signif-
icantly computationally cheaper and, as shown in Bellman [1], it has a simple structure
expressible in terms of an index function, which depends only on the total observed number
of successes s and failures f of the unknown process. Such function is obtained by com-
paring a known arm with success rate p to the unknown arm with expected success rate
s/(s + f) and returning the value of p, denoted by p∗, that would make the decision maker
indiﬀerent between these two arms. This p∗ value is the index function, which can be used
for expressing the optimal policy as a threshold policy: allocate patients to the unknown
arm as long as s/(s + f) > p∗. Gittins and Jones [9] showed that Bellman’s index function
can be used to express the optimal solution to the K + 1-armed inﬁnite discounted bandit
problem: simply allocate patient j to the treatment with the highest GI p∗ (for a given pair
of s and f) at time t.
Speciﬁcally, the calibration method uses Dynamic Programming to approximate the GI
values based on this idea, as explained in Gittins and Jones [10]. This index computation
method solves, for a grid of p values (the size of which determines the accuracy of the
resulting index values approximations), the following problem:
V ∗(s, f, p) = max
{
p
1− d ,
s
s + f
(1 + d V ∗(s + 1, f, p)) +
f
s + f
(d V ∗(s, f + 1, p))
}
. (3)
The set of values of (s, f) (i.e., successes and failures observed in the unknown arm) and p
for which the two expressions in the maximum in (3) are equal imply that the GI value for
an arm with a prior Be(s, f) and discount factor d is p.
Calculations of the Gittins indices have been reported in brief tables as in Gittins [7,8].
Improvements to the eﬃciency of this index computing method have since been proposed
by Katehakis and Veinott Jr [11], Katehakis and Derman [12]. Table 1 reports values of the
GI for diﬀerent combinations of (s, f) and d = 0.999.
2.3. The WI
Of course, patient populations in general (not only those in rare diseases) are never of an
inﬁnite size, so the inﬁnite-horizon assumption is not a sensible one. For the rare diseases
case, we are interested in the case where N is not only ﬁnite but relatively small to run
a traditional randomized trial to select a best treatment. Thus, the relevant problem for
optimal treatment allocation designs is as deﬁned in (2), with a ﬁnite value of N . However,
the Gittins Theorem does not apply to this case, and thus the index function as deﬁned
for the inﬁnite-horizon variant does not exist [see Berry and Fristedt [3]]. Indeed, a solution
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could in theory be obtained via DP, but for reasons already stated, this would be impractical
even for relatively small-scale scenarios. In the inﬁnite-horizon problem, when making the
treatment decision for any patient j there is always an inﬁnite number of possible sample
observations to be drawn from any of the treatments. This is no longer the case in a ﬁnite-
horizon problem, and the value of an outcome history is not the same when the treatment
allocation process is about to start than when it is about to end. The ﬁnite-horizon problem
analysis is thus more complex, because these transient eﬀects must be considered for the
characterization of the optimal policy.
Speciﬁcally, a cut-oﬀ value similar to the GI will depend on the number of patients
treated (or equivalently, the number of patients remaining in the population to treat).
Therefore, for every patient j we could compute an index value that will now depend not
only on the number of observed successes and failures per arm, but also on the number of
patients treated. Such an index could be computed using the calibration method solving,
for a grid of p values, the following DP problems:
V ∗N−1(s, f, p,N) = max
{
p ,
s
s + f
}
,
V ∗j (s, f, p,N) = max
⎧⎨
⎩p
N−1∑
t=j
dN−t,
s
s + f
(
1 + d V ∗(j+1)(s + 1, f, p,N)
)
+
f
s + f
(
d V ∗(j+1)(s, f + 1, p,N)
)}
, j = 0, . . . , N − 2,
(4)
where in this case, the set of values of (s, f) (i.e., successes and failures observed in the
unknown arm), N , j and p for which the two expressions deﬁning the maximum value of
V ∗j (s, f, p,N) in (4) are equal determine that the ﬁnite-horizon index value for an arm with
a prior Be(s, f), N − j patients to treat and discount factor d is p∗(N−j). For instance, for
the last patient in the trial, that is, for j = N − 1, the associated index value would just
be p∗(N−1) = (s/s + f), the treatment’s posterior mean. Note that, if d < 1 then
∑N
t=j d
t =
(1− dN−j/1− d), whereas if d = 1 then ∑Nt=j dt = N − j.
In fact, as mentioned in Villar, Bowden, and Wason [16], such index policy can also
be derived based on an equivalent reformulation of (2) in which the information state of
each arm is augmented, adding to the number of observed successes and failures per arm,
the number of remaining patients that can be assigned to the K + 1 treatments. Such a
reformulation is an inﬁnite-horizon Restless MABP [14]. The restlessness of bandit models
refers to the fact that each arm’s information state continues to evolve even when not
selected for being active. In this particular case, the fact that the number of remaining
patients is part of every arm’s information state and this varies for all arms (allocated
or not) over the trial, introduces the restless feature ﬁrst proposed by the seminal work by
Whittle [20]. Index strategies for Restless MABP do not always exist and if they do, they are
not necessarily optimal. Whittle [20] deployed a Lagrangian relaxation and decomposition
approach to derive an index function, analogous to GI, which has become known as the WI.
Whittle further conjectured that the index policy for the restless variant enjoys a form of
asymptotic optimality (in terms of the ETD rewards achieved), a property later established
by Weber and Weiss [19] under certain conditions. Typically, the resulting heuristic has
been found to be nearly optimal in various models.
In general, establishing the existence of an index function for a restless MABP (i.e.,
showing its indexability) and computing it is a tedious task. In some cases, the suﬃcient
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indexability conditions (SIC) introduced by Nin˜o-Mora [13] can be applied for both pur-
poses. Nevertheless, the restless bandit reformulation of (2) is always indexable. Such a
property can either be shown by means of the SIC approach or simply using the seminal
result in Bellman [1], by which the monotonicity of the optimal policies can be ensured,
allowing us to focus attention on a nested family of stopping-times. Moreover, the computa-
tion of the WI can be done as a modiﬁed version of the GI [see Proposition 3.1 in Nin˜o-Mora
[15]] in which the search of the optimal stopping time is truncated to be less than or equal
to the number of remaining patients to be treated (and this is repeated for each patient to
be treated).
Table 2–4 include some values of the Whittle indices for diﬀerent combinations of (s, f)
and d = 0.999 when N = 200, and the number of remaining observations is respectively
allowed to be N − j = 50, N − j = 100 and N − j = 150.
Again, the WI rule assigns a number from these tables to every treatment, based on
the values of s and f and on the number of remaining periods n− j, and then prioritizes
sampling the one with highest value.
Table 2. The WI values for an information vector of s successes and
f failures, N − j = 50, d = 1 and where the size of the trial is N = 200.
f/s 1 2 3 4 5 6
1 0.8246 0.8792 0.9042 0.9192 0.9294 0.9370
2 0.6378 0.7373 0.7886 0.8210 0.8437 0.8607
3 0.5047 0.6209 0.6871 0.7317 0.7636 0.7882
4 0.4111 0.5292 0.6040 0.6553 0.6933 0.7233
5 0.3435 0.4603 0.5349 0.5907 0.6328 0.6660
6 0.2929 0.4048 0.4800 0.5357 0.5804 0.6162
Table 3. The WI at N − j = 100.
f/s 1 2 3 4 5 6
1 0.8659 0.9071 0.9258 0.9371 0.9448 0.9505
2 0.6949 0.7797 0.8227 0.8497 0.8685 0.8826
3 0.5610 0.6674 0.7261 0.7653 0.7933 0.8146
4 0.4643 0.5754 0.6441 0.6905 0.7252 0.7521
5 0.3914 0.5040 0.5748 0.6264 0.6652 0.6956
6 0.3365 0.4458 0.5174 0.5709 0.6127 0.6460
Table 4. The WI at N − j = 150
f/s 1 2 3 4 5 6
1 0.8859 0.9207 0.9365 0.9460 0.9525 0.9573
2 0.7252 0.8019 0.8406 0.8648 0.8817 0.8942
3 0.5925 0.6930 0.7476 0.7837 0.8096 0.8291
4 0.4949 0.6018 0.6667 0.7103 0.7431 0.7682
5 0.4196 0.5291 0.5977 0.6468 0.6837 0.7127
6 0.3625 0.4700 0.5391 0.5913 0.6314 0.6633
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2.4. Other Index Strategies
The index strategies described in the previous sections are an example of simple and natural
rules that dynamically prioritize resource allocation among diﬀerent stochastic projects.
However, the class of index policies is still overwhelmingly large, and despite all being
computationally tractable only in special cases they result in well performing or even optimal
policies. Index strategies, in general, deﬁne a priority index for each treatment as a function
of its information state (observed successes and failures). The associated priority-index
heuristic allocates for each patient the treatment with currently largest index value.
In this paper, we shall also consider three alternative priority-index heuristics for the
ﬁnite horizon multi-armed bandit problem: the Myopic Index (MI), FI and a GI heuristic.
The MI is perhaps the simplest priority-index rule, which has usually been proposed as a
heuristic for addressing several optimization problems. In the context of this problem, the
MI uses the posterior mean of each treatment after observing the outcome of a patient j to
make the decision for patient j + 1.
FI is based on work by Feldman [6], which showed that the optimal solution to a special
case of the two-armed bandit problem in which we know the possible values for the two
arms’ success rates are pA and pB but we do not know which arm has which success rate
admits a simple index rule. In terms of this simple problem both FI and the optimal rule
would allocate treatment k whenever the current probability that pk = max{pA, pB} is at
least 1/2. This is equivalent to a much simpler rule in which if s0 − f0 ≥ s1 − f1 then it is
optimal to allocate treatment 0 and otherwise it is optimal to allocate treatment 1. Berry
[2] was the ﬁrst to propose and assess the use of FI as a heuristic solution for the general
two-armed bandit problem. In this paper we shall extend FI as a heuristic for the multi-
armed case by letting the index per arm be deﬁned as sk − fk and then applying the index
rule, that is, allocating the treatment with the highest index, breaking ties at random.
Additionally we will deﬁne a GI heuristic by using the Gittins index for a given discount
factor value d to make decisions for all patients in the population. This will imply that the
same table of values will be used across the population simplifying computations when
comparing it with the WI. Notice that an alternative way to deﬁne a GI heuristic would be
to choose a diﬀerent discount factor for each patient. The rationale behind the choice of each
discount factor of dj is that if the discount factor dj is interpreted as the probability that
the trial will continue after each patient, then the probability that the remaining patient
population is of size N − j (or smaller) can be computed as (1− dN−jj ) and we would
like this probability to be approximately 1. For example, if j = N − 1 (the last patient
in the population is to be treated) then dN−1 = 0 so that (1− dN−jj ) = 1. Alternatively,
if j = 0 (the ﬁrst patient in the population is to be treated) and N = 100 then dN−1 =
0.9 makes (1− dN−jj ) ≈ 1 (or in other words it makes the expected size of the remaining
patient population of size 1(1−dj) = 100). However, using this GI heuristic would result in
a computational cost very similar to that of the WI as a diﬀerent index table per patient
would be needed.
3. NUMERICAL RESULTS
3.1. Two-armed Trials
In Berry [2] numerical (exact) results were ﬁrst shown for FI and the optimal rule in context
of the two-armed bandit problem in which the joint density of (p1, p2) before the start of
the trial is the product of two uniform distributions (corresponding to the clinical equipoise
principle by which there is genuine uncertainty in the expert medical community over which
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Table 5. Exact computations: The expected proportion of suc-
cesses of the diﬀerent patient allocation rules for the two-armed
bandit problem with uniform priors.
1. Expected proportion of successes when
a1 = b1 = a2 = b2 = 1
n τ∗ WI(N) GI(0.9) FI MI
1 0.50000 0.50000 0.50000 0.50000 0.50000
2 0.54167 0.54167 0.54167 0.54167 0.54167
3 0.55556 0.55556 0.55556 0.55556 0.55556
4 0.56944 0.56944 0.56944 0.56944 0.56875
5 0.57778 0.57778 0.57778 0.57611 0.57694
6 0.58472 0.58472 0.58472 0.58403 0.58371
7 0.59028 0.59028 0.59016 0.58812 0.58910
8 0.59494 0.59494 0.59457 0.59346 0.59367
9 0.59866 0.59866 0.59841 0.59625 0.59727
10 0.60218 0.60215 0.60197 0.60017 0.60058
15 0.61410 0.61406 0.61386 0.61049 0.61164
20 0.62156 0.62147 0.62125 0.61746 0.61827
25 0.62679 0.62670 0.62636 0.62162 0.62271
30 0.63066 0.63061 0.63011 0.62515 0.62594
35 0.63371 0.63363 0.63301 0.62743 0.62840
40 0.63617 0.63609 0.63533 0.63410 0.63034
60 0.64271 0.64265 0.64131 0.63460 0.63526
80 0.64657 0.64651 0.64468 0.63757 0.63800
100 0.64918 0.64912 0.64687 0.63943 0.63975
treatment will be beneﬁcial, if any). The results in Berry [2] show how this simple rule has
a very good performance, as depicted in Table 5, its suboptimality gap for N = 100 is of
only 1.5%.
We have extended the exact numerical results included in Berry [2] in Table 5 by also
including the results for the other rules considered in this paper: MI, GI(d = 0.9) and WI.
The results indicate that the MI rule and FI are a priori practically equivalent in their
performance (although MI appears to slightly outperform FI for N > 4). As well, the GI
and WI are also very similar in their performance but WI always outperforms the GI
approach. On the other hand, both GI and WI are also almost equivalent to the optimal
rule. According to these results, the simplest approaches perform suﬃciently well to justify
getting into the complexity of applying the index policies, at least for when K = 2 and
n ≤ 100. However, as shown in Table 6, once a ﬁxed pair of success rates is assumed there
are important diﬀerences that are worth pointing out, that is, in terms of the resulting value
function V ∗(N,π) and the mean proportion of patients allocated to a best arm (when it
exists) p∗. These diﬀerences in performance are explained because the results in Table 5
correspond to averaging over all possible values of p1, p2, whereas the results in Table 6
correspond to a particular point in the parameter space of (p1, p2).
Table 6 shows the results of applying each of the patients allocation rule when the
true (though unknown to the decision maker) vector of parameters is equal to p = (0.3, 0.5)
after 104 trial replicas by simulation. The results show that the WI is superior to all other
rules in terms of p∗. These results also suggest that FI is superior to the MI rule, both
in terms of p∗ and its resulting value function. The table also suggests that while for the
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Table 6. Computations through simulations: The expected proportion of patients allo-
cated to the best arm p∗ and the expected proportion of successes of the diﬀerent patient
allocation rules for the two-armed bandit problem starting with uniform priors when
p1 = 0.3 and p2 = 0.5.
2. Expected proportion of patients allocated to the best arm and
Expected proportion of successes when p1 = 0.3 and p2 = 0.5
WI(N) GI(0.9) FI MI
N p∗ V ∗(N,πWI) p∗ V ∗(N,πGI) p∗ V ∗(N,πFI) p∗ V ∗(N,πMI)
50 0.7652 0.4604 0.7364 0.4498 0.7389 0.4518 0.7085 0.4414
100 0.8538 0.4723 0.8283 0.4688 0.8094 0.4625 0.7493 0.4528
150 0.8717 0.4769 0.8573 0.4758 0.8432 0.4705 0.7892 0.4619
200 0.9051 0.4821 0.8886 0.4802 0.8584 0.4738 0.7928 0.4592
250 0.9205 0.4851 0.9029 0.4825 0.8770 0.4763 0.8207 0.4654
300 0.9284 0.4868 0.9197 0.4857 0.8877 0.4789 0.8260 0.4650
WI and GI the diﬀerences tend to vanish as N grows, the opposite happens for FI and
MI. Note that the relative increase in the mean proportion of patients assigned to best
treatment of using the best index based approach (i.e., WI) over the simpler approaches
goes from 0.08 and 0.036 (for N = 50) to 0.124 and 0.046 (for N = 300) for the MI and FI,
respectively.
3.2. Multi-armed Trials
Besides the need for designs speciﬁcally tailored for small populations, in some therapeutic
areas, such as in cancer treatment, there are several possible agents awaiting trials, and
thus a major challenge in their development is the considerable time and resources needed
for conducting separate randomized clinical trials. Multi-arm trials in which several novel
treatments are compared in the same trial have many advantages: they are more eﬃcient
and cheaper, since a shared control group is used; more treatments can be simultaneously
tested with a limited set of patients; and tend to be more popular with patients as a greater
chance of being allocated to a new/superior treatment is perceived by them or their families.
Moreover, the beneﬁts of adaptive rules such as the ones considered in this paper should be
the greatest as the number of arms included in the trial grows.
In this section, we will illustrate this advantage through an exact computation for the
case K = 3 and through simulation results of trials involving three and more arms. All of the
index rules here considered are deployed as follows: for every patient allocate the treatment
with the current highest index value, breaking ties at random.
The results in Table 7 show how the diﬀerence in the performance of the simpler heuris-
tics (MI and FI) tends to be further away from the optimal value for a given number of
patients (when compared with the two-armed values in Table 5). The suboptimality gap of
the MI rule goes from 0.65% when K = 2 and N = 25 to 1.07% when K = 3 and N = 25.
On the other hand, for the WI and GI this suboptimality gap also increases, but it is still
very close to the optimal value for every N . For example, the suboptimality gap of the WI
rule goes from 0.01% when K = 2 and N = 25 to 0.03% when K = 3 and N = 25.
In Table 8, we show results of simulations for larger number of arms and diﬀerent pop-
ulations sizes. The advantage of the WI and GI rules over the myopic approaches becomes
larger as the number of arms and the patient horizon grows. For the case N = 300 and K = 7
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Table 7. Exact computations: the expected proportion of suc-
cesses of the diﬀerent patient allocation rules for the three-armed
bandit problem with uniform priors.
2. Expected proportion of successes when
a1 = b1 = a2 = b2 = a3 = b3 = 1
n τ∗ WI(N) GI(0.9) FI MI
1 0.50000 0.50000 0.50000 0.50000 0.50000
2 0.54166 0.54166 0.54166 0.54166 0.54166
3 0.56944 0.56944 0.56944 0.56944 0.56944
4 0.58681 0.58681 0.58681 0.58634 0.58634
5 0.60139 0.60139 0.60139 0.60019 0.60019
6 0.61273 0.61273 0.61273 0.61114 0.61114
7 0.62153 0.62153 0.62141 0.61939 0.61965
8 0.62894 0.62894 0.62847 0.62656 0.62685
9 0.63549 0.63549 0.63494 0.63273 0.63310
10 0.64096 0.64096 0.64051 0.63787 0.63831
15 0.66083 0.66062 0.66034 0.65607 0.65653
20 0.67329 0.67322 0.67276 0.66715 0.66744
25 0.68207 0.68190 0.68130 0.67474 0.67480
30 0.68863 0.68854 0.68766 0.68013 0.68031
the absolute diﬀerence in the mean proportion of successes between WI and MI is approxi-
mately 0.06, which represents 18 patients. It is worth pointing out that FI outperforms the
MI rule in every instance though the diﬀerence is less than 10−3. This diﬀerence could be
within Montecarlo error if the exact diﬀerence is less than 10−4 as suggested by the results
in Table 7.
3.3. Understanding the WI Rule
In this section, we look into the situations under which the WI rule fails to recover the
optimal action so as to learn about the biases and mistakes than can result from its use in
practice. For simplicity we focus on the two-armed bandit case with an initial uniform prior
on both arms.
There are instances in which the WI rule makes a deterministic decision, while the
optimal action is to randomize the treatments. However, these instances do not aﬀect the
resulting value function, because both actions are equally optimal. For example, this occurs
for N = 8 and 5 patients have been treated with all of them allocated to one of the arms
and three successes and two failures observed. The optimal decision for the patient 6 is
to randomize him/her to the two treatments with equal probability The WI rule however,
chooses the more explored arm because its index is 0.6049, whereas the unexplored arm has
an index of 0.5909.
The instances in which the WI rule makes a allocation that diﬀers from the optimal
one and it aﬀects the resulting value function are those that actually introduce a bias or
mistake. The ﬁrst of these instances happens for N = 10. The only diﬀerence between the
actions selected by the WI and the optimal rule occur for only two instances out of all the
possible trial histories (410). They correspond to the case in which seven patients have been
treated and six have been allocated to the ﬁrst arm n1 = 6, with 2 successes s1 = 2 and
four failures f1 = 4 and one observation was allocated to the second arm n2 = 1 with s1 = 0
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Table 8. Computations through simulations: The expected
proportion of successes of the diﬀerent patient allocation rules
for the multi-armed bandit problem with uniform priors as the
number of arms grows. Number of simulations: 104.
2. (Simulated) Expected proportion of
successes for diﬀerent K + 1 and ak = bk = 1 ∀k
K + 1 N WI(N) GI(0.9) FI MI
3 50 0.69998 0.69418 0.69139 0.68764
4 50 0.74251 0.73112 0.71733 0.72062
5 50 0.76086 0.74831 0.73494 0.73406
6 50 0.77699 0.76223 0.74734 0.74392
7 50 0.78765 0.76882 0.76882 0.74756
3 100 0.72044 0.71546 0.70069 0.69746
4 100 0.76041 0.75474 0.73722 0.73211
5 100 0.78468 0.77740 0.75286 0.74976
6 100 0.80564 0.79454 0.76554 0.76360
7 100 0.81610 0.80490 0.77173 0.76763
3 150 0.72887 0.72065 0.71434 0.70098
4 150 0.77154 0.76511 0.74128 0.73770
5 150 0.79607 0.78962 0.76022 0.75361
6 150 0.81826 0.80795 0.77028 0.76826
7 150 0.82904 0.82564 0.77969 0.77623
3 200 0.73038 0.72806 0.70869 0.70422
4 200 0.77938 0.77465 0.74327 0.73923
5 200 0.80376 0.79647 0.76827 0.75880
6 200 0.82344 0.82099 0.77627 0.77205
7 200 0.83853 0.83263 0.83263 0.78078
3 250 0.73209 0.73395 0.70784 0.70852
4 250 0.77532 0.77750 0.75175 0.74114
5 250 0.80925 0.80394 0.76483 0.76463
6 250 0.82318 0.82946 0.77777 0.77369
7 250 0.84381 0.83838 0.78587 0.78430
3 300 0.73459 0.73450 0.71403 0.71251
4 300 0.78174 0.77852 0.74749 0.74218
5 300 0.80761 0.80962 0.77007 0.76422
6 300 0.83119 0.83053 0.78250 0.77814
7 300 0.84643 0.84440 0.78740 0.78656
and f1 = 1. The Whittle indices (for d = 1) respectively are 0.4054 and 0.4000. Therefore,
the action selected by the Whittle rule is to allocate treatment 1 to patient 8, whereas the
optimal action is to allocate treatment 2 (which is less explored). By symmetry the case of
the same history for the alternate arms is the same.
Basically, the mistake happens in those instances in which the diﬀerence between the
indices is small (in the above case of 0.0054), which means that the arms have a very
similar posterior mean, but arms have a signiﬁcant diﬀerence in how much they have been
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explored. In that case, the WI selects the arm with the highest immediate expected eﬀect,
while the optimal action is to allocate the one with the smaller index, but which has been
less explored. This indicates that the instances in which the WI makes a wrong decision
are caused by the WI being slightly more myopic than than the optimal rule would be.
Of course, there are no suboptimality instances for the last patient in the trial (because
both the optimal and the WI rules allocate that patient to the treatment with highest
posterior mean) and there are no suboptimal instances in the ﬁrst patients because the
arms have not been signiﬁcantly diﬀerently explored if they all start with the same initial
priors.
Figure 1. The ML phase (or, the size of the trial phase) and the population size for the
GI, WI and a the optimal size of a FE randomized learning phase.
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3.4. Trial Design, Population Size and Learning/Earning Stages
The relative merits of using decision theory and a goal to maximize overall health to decide
on a trial’s size and its design as opposed to using a traditional approach depend on the
patient horizon. In Cheng, Su, and Berry [5] the authors illustrate this by addressing the
problem of determining the optimal size of the initial learning stage (or trial) using a
decision-analytic approach. The main result is that for a two-armed trial and a learning
phase that takes the form of a ﬁxed equal (FE) randomized trial, the optimal size of the
initial learning phase under initial equipoise depends of the order of magnitude of the square
root of the population size N .
Index-based rules have a learning phase and an earning phase whose sizes vary according
to the particular sample data that is observed in a trial realization and in the case of the
WI, according to the patient horizon (or the number of remaining patients to treat). In this
section of the paper, we compute by simulation the size of the ML phases of the GI and WI
Table 9. The simulated expected proportion of patients allo-
cated to the best treatment, the mean number of successes and the
ML phase of the diﬀerent patient allocation rules for the two-armed
bandit problem with p1 = 0.3 and p2 = 0.5 for {N = 50, 150}.
(p1, p2) N Rule P
∗ ENSN=50 ML
(0.3, 0.4) 50 GI(0.9) 0.6246 18.23 41
(0.3, 0.5) 50 GI(0.9) 0.7323 22.59 37
(0.3, 0.6) 50 GI(0.9) 0.8166 27.61 31
(0.3, 0.7) 50 GI(0.9) 0.8692 33.04 24
(0.3, 0.4) 50 WI(N) 0.6584 18.40 24
(0.3, 0.5) 50 WI(N) 0.7608 22.74 19
(0.3, 0.6) 50 WI(N) 0.8411 27.93 13
(0.3, 0.7) 50 WI(N) 0.8883 33.41 8
(0.3, 0.4) 50 FE 0.5427 17.71 8
(0.3, 0.5) 50 FE 0.6381 21.31 8
(0.3, 0.6) 50 FE 0.6917 25.38 8
(0.3, 0.7) 50 FE 0.7712 30.47 8
(p1, p2) T Rule P
∗ ENSN=150 ML
(0.3, 0.4) 150 GI(0.9) 0.7308 55.96 112
(0.3, 0.5) 150 GI(0.9) 0.8635 70.80 90
(0.3, 0.6) 150 GI(0.9) 0.9210 86.92 72
(0.3, 0.7) 150 GI(0.9) 0.9468 102.53 58
(0.3, 0.4) 150 WI(N) 0.7522 55.96 59
(0.3, 0.5) 150 WI(N) 0.8831 71.92 41
(0.3, 0.6) 150 WI(N) 0.9363 87.79 28
(0.3, 0.7) 150 WI(N) 0.9558 103.17 18
(0.3, 0.4) 150 FE 0.6270 54.60 13
(0.3, 0.5) 150 FE 0.7388 66.93 13
(0.3, 0.6) 150 FE 0.8245 82.72 13
(0.3, 0.7) 150 FE 0.8847 98.34 13
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rules in a two-armed scenario and compare then with the approach suggested in Cheng, Su,
and Berry [5].
In Figure 1, the simulations results of 104 replicas are depicted. We have deﬁned the
mean learning (ML) phase of the WI and GI rules as the mean number of allocations after
which the treatment allocations are always to the same treatment (i.e., until the last patient
in the population) when using these index rules. For the traditional FE randomized trial of
optimal size as in Cheng, Su, and Berry [5], the ML has been approximated by √(N).
The ﬁgure shows that the GI has a larger exploration phase than the other two approaches.
The WI has an exploration phase that is larger than the FE approach, and it is only similar
to it when N is the smallest. It is important to note that this larger learning phase results
in a larger expected proportion of successes not only by being larger in size, but also by
not being constrained to be balanced, that is, the WI explores more and it does so in a
unbalanced fashion.
Table 10. The expected proportion of patients allocated to the best treat-
ment, the mean number of successes and the ML phase of the diﬀerent patient
allocation rules for the two-armed bandit problem with p1 = 0.3 and p2 = 0.5
for N = {200, 300}.
(p1, p2) T Rule P
∗ ENS200 ML
(0.3, 0.4) 200 GI(0.9) 0.7633 75.41 142
(0.3, 0.5) 200 GI(0.9) 0.8954 96.21 111
(0.3, 0.6) 200 GI(0.9) 0.9373 116.99 89
(0.3, 0.7) 200 GI(0.9) 0.9577 137.43 71
(0.3, 0.4) 200 WI(N) 0.7780 75.49 76
(0.3, 0.5) 200 WI(N) 0.8976 96.33 53
(0.3, 0.6) 200 WI(N) 0.9454 117.26 37
(0.3, 0.7) 200 WI(N) 0.9671 138.30 23
(0.3, 0.4) 200 FE 0.5975 73.10 15
(0.3, 0.5) 200 FE 0.7314 89.39 15
(0.3, 0.6) 200 FE 0.8390 111.33 15
(0.3, 0.7) 200 FE 0.9051 132.08 15
(p1, p2) T Rule P
∗ ENS300 ML
(0.3, 0.4) 300 GI(0.9) 0.8112 114.32 196
(0.3, 0.5) 300 GI(0.9) 0.9242 145.73 144
(0.3, 0.6) 300 GI(0.9) 0.9556 176.77 116
(0.3, 0.7) 300 GI(0.9) 0.9716 207.07 92
(0.3, 0.4) 300 WI(N) 0.8066 114.16 106
(0.3, 0.5) 300 WI(N) 0.9246 145.85 68
(0.3, 0.6) 300 WI(N) 0.9624 176.87 47
(0.3, 0.7) 300 WI(N) 0.9770 208.27 34
(0.3, 0.4) 300 FE 0.6223 109.12 18
(0.3, 0.5) 300 FE 0.7549 135.57 18
(0.3, 0.6) 300 FE 0.8782 167.50 18
(0.3, 0.7) 300 FE 0.9073 198.86 18
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In Tables 9 and 10, we illustrate the same idea in diﬀerent contexts. We assume diﬀerent
values for (p1, p2) and we apply the diﬀerent allocations rules. We then compute the ML
phase for the index rules, the mean proportion of patients in the population allocated to
the best arm (P ∗) and the mean number of successes in the population (ENSN ). We do this
for increasing sizes of the population with the disease or patient horizon.
The results in the tables show that the WI and GI reduce their learning phases’ size
when the diﬀerence between p1 and p2 is larger. However, the GI will always have a larger
average size of a learning phase than the WI. The results also indicate that even when the GI
and WI result in practically identical values of ENS, the WI will have an advantage in terms
of the proportion of patients allocated to the best treatment. The results also suggest that
the larger the diﬀerence between the treatments and the smaller the population size, the
more important the advantage of the index rules over an FE approach. As well, the bandit
results perform as well as the other alternatives under the presence of equal treatments
success rates.
4. DISCUSSION
A common deﬁnition of a rare disease is that of a disease aﬀecting no more than 5 per
10,000 persons. Yet, rare diseases are not so rare. According to the EU Implementation
report on the Commission Communication on Rare Diseases, between 27 and 36 million
people in Europe are aﬀected by a rare diseases. Further, this number is expected to raise
with the improvements of diagnosis methods and the advance of genetics partitions diseases
into smaller entities. Developing statistical methods speciﬁc for drug development for rare
diseases is of critical importance and a current health policy priority due to both this
expected increase in rare diseases prevalence and the current diﬃculties that limit running
clinical trials for these conditions.
In a rare disease setting, the number of patients available for running a trial is signif-
icantly smaller than the number required to run a standard randomized trial. Moreover,
randomizing patients to treatments so as to learn the most about them when few or no
patients would beneﬁt from that learning is highly questionable. Instead, treatment deci-
sions for the patients recruited in a trial (or with the patients in the whole population, if
that would be known) can be guided by the goal of learning about the available treatment
options just enough as to maximize eﬀective treatment for the largest number of patients
with the disease. This goal can be successfully implemented assuming a decision-analytic
approach that would be able to assist physicians both in their learning about treatments
eﬃcacy and in their treatment decision making.
Optimal designs, from this eﬀective treatment perspective, have been long studied in the
decision-analytic theoretical literature as “bandit” models. Among other limitations to their
use in a clinical settings [see Villar, Bowden, and Wason [16]], computational complexity
and the diﬃculty of implementation and interpretation of designs based on their optimal
rule is still binding. Developing simple, practical and computational feasible approaches to
“bandit” problems is an open an active area of research in sequential allocation problems in
general and beyond clinical trials. In this paper, we contributed by presenting calculations
(both exact and simulated) that suggest that the advantages of the nearly-optimal bandit
rules based on non-MI policies are increased when the number of arms grows and the disease
under study aﬀects a relatively small estimated number of patients. The potential patient
beneﬁt gain resulting from treatment decisions based on these ideas suggest that their use
in practice could help provide answers to the current challenges faced by drug development
for rare conditions.
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Further research is needed to overcome other limitations to bandit strategies besides
the computational one and also to determine some general conditions under which arms are
selected or dropped when using the index rules.
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